This retrospective case series reports minimum 5-year outcomes of arthroscopic superior capsular reconstruction (SCR) using acellular human dermal allograft. Patients had operatively irreparable posterosuperior rotator cuff tears treated by a single surgeon. The study asks whether clinical gains hold up and whether the graft and joint stay structurally sound over the midterm.
When you counsel a young, active patient with an irreparable posterosuperior cuff tear, frame SCR honestly: it reliably relieves pain but the graft usually fails. This series shows a clean dissociation between clinical and structural outcomes. ASES and SANE held up at 6 years while 66% of grafts tore completely and arthropathy marched on.
The mental model is the biologic spacer. SCR re-centers the head and boosts acromiohumeral distance early, but once the graft ruptures the AHI falls below baseline and Hamada grade climbs.
The practical payoff is patient selection and expectation-setting. SCR is a resource-intensive, joint-preserving interim option that may delay reverse arthroplasty, but it does not restore overhead strength and likely does not change the disease's trajectory. Remember that prior SCR can worsen later reverse arthroplasty outcomes, so reserve it for patients with a good chance of graft healing.
This retrospective case series reports minimum 5-year outcomes of arthroscopic superior capsular reconstruction (SCR) using acellular human dermal allograft. Patients had operatively irreparable posterosuperior rotator cuff tears treated by a single surgeon. The study asks whether clinical gains hold up and whether the graft and joint stay structurally sound over the midterm.
When you counsel a young, active patient with an irreparable posterosuperior cuff tear, frame SCR honestly: it reliably relieves pain but the graft usually fails. This series shows a clean dissociation between clinical and structural outcomes. ASES and SANE held up at 6 years while 66% of grafts tore completely and arthropathy marched on.
The mental model is the biologic spacer. SCR re-centers the head and boosts acromiohumeral distance early, but once the graft ruptures the AHI falls below baseline and Hamada grade climbs.
The practical payoff is patient selection and expectation-setting. SCR is a resource-intensive, joint-preserving interim option that may delay reverse arthroplasty, but it does not restore overhead strength and likely does not change the disease's trajectory. Remember that prior SCR can worsen later reverse arthroplasty outcomes, so reserve it for patients with a good chance of graft healing.